A phase II, randomized study of aprepitant in the prevention of chemotherapy‑induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients

Aridome,Kuniaki; Mori,Shin‑Ichirou; Baba,Kenji; Yanagi,Masayuki; Hamanoue,Masahiro; Miyazono,Futoshi; Tokuda,Kouki; Imamura,Hiroshi; Ogura,Yoshito; Kaneko,Kouichi; Kijima,Fumio; Maemura,Kousei; Ishigami,Sumiya; Natsugoe,Shoji

doi:10.3892/mco.2015.724

A phase II, randomized study of aprepitant in the prevention of chemotherapy‑induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients

Authors:
- Kuniaki Aridome
- Shin‑Ichirou Mori
- Kenji Baba
- Masayuki Yanagi
- Masahiro Hamanoue
- Futoshi Miyazono
- Kouki Tokuda
- Hiroshi Imamura
- Yoshito Ogura
- Kouichi Kaneko
- Fumio Kijima
- Kousei Maemura
- Sumiya Ishigami
- Shoji Natsugoe
View Affiliations

Affiliations: Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medicine, Kagoshima University, Sakuragaoka, Kagoshima 890‑8520, Japan, Department of Surgery, Imakiire General Hospital, Kagoshima 892‑8502, Japan, Department of Surgery, Kagoshima Prefectural Satsunan Hospital, Minamisatsuma, Kagoshima 897-1123, Japan, Department of Digestive Surgery, Kobayashi City Hospital, Kobayashi, Miyazaki 886‑0004, Japan, Department of Surgery, Izumi Regional Medical Center, Akune, Kagoshima 899-1611, Japan, Department of Surgery, Kagoshima Kouseiren Hospital, Kagoshima 890‑0061, Japan, Department of Surgery, Kaneko Hospital, Ichikikushikino, Kagoshima 896‑0055, Japan, Department of Surgery, Saiseikai Sendai Hospital, Satsumasendai, Kagoshima 895‑0074, Japan
Published online on: December 31, 2015 https://doi.org/10.3892/mco.2015.724
Pages: 393-398

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to study the efficacy of aprepitant in the prevention of chemotherapy‑induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) for colorectal cancer (CRC), and comprised a multicenter, phase II, open‑label, randomized, parallel comparative study conducted as part of the Kagoshima aprepitant study for colon cancer in Japan. Patients with advanced or recurrent CRC were treated with standard MEC regimens (FOLFOX, XELOX or FOLFIRI) and received either standard chemotherapy [5‑hydroxytryptamine-3 receptor antagonist (5‑HT3 RA) + dexamethasone] or aprepitant regimen chemotherapy (5‑HT3 RA + reduced‑dose dexamethasone + aprepitant). The primary endpoint of the present study was the proportion of patients who achieved a complete response (CR) during the overall, acute, and delayed phases of the first planned chemotherapy cycle. Secondary endpoints were complete protection, the proportions of patients without emetic episodes or nausea, patients with no more than moderate nausea during the overall, acute and delayed phases, and the time to treatment failure. The CR rates in the overall, acute and delayed phases were similar in the aprepitant and the standard‑regimen groups. Additionally, there were no significant differences in secondary endpoints between the two groups. In summary, aprepitant in combination with 5‑HT3 RA and reduced‑dose corticosteroids was well tolerated and effective in preventing CINV associated with moderately emetogenic antitumor agents in Japanese patients with CRC.

View Figures

View References

1	Oo TH and Hesketh PJ: Drug insight: New anti-emetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol. 2:196–201. 2005. View Article : Google Scholar : PubMed/NCBI
2	Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, Kerr D, Khanna S, Smyth J and Coleman R: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 49:295–304. 1992. View Article : Google Scholar : PubMed/NCBI
3	Sigsgaard T, Herrstedt J, Andersen LJ, Havsteen H, Langer SW, Kjaerbøl AG, Lund H, Kjaer M and Dombernowsky P: Granisetron compared with predonisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 80:412–418. 1999. View Article : Google Scholar : PubMed/NCBI
4	Sigsgaard T, Herrstedt J, Handberg J, Kjaer M and Dombernowsky P: Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as anti-emetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. 19:2091–2097. 2001.PubMed/NCBI
5	American Society of Clinical Oncology. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ and Grunberg SM: American society of clinical oncology guideline for anti-emetics in oncology: Update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
6	Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 23:2822–2830. 2005. View Article : Google Scholar : PubMed/NCBI
7	Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T and Schmoll HJ: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer. 18:423–431. 2010. View Article : Google Scholar : PubMed/NCBI
8	Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, Herrstedt J, Saito M and Tonato M: Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer. 19(Suppl 1): S57–S62. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in. 2008 GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
10	Van Cutsem E and Oliveira J: ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): S61–S63. 2009.
11	Yoo PS, Lopez-Soler RI, Longo WE and Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 6:202–207. 2006. View Article : Google Scholar : PubMed/NCBI
12	de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.PubMed/NCBI
13	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
14	Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
15	Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, et al: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 22:2084–2091. 2004. View Article : Google Scholar : PubMed/NCBI
16	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
17	André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
18	Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K and Schmoll HJ: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 29:1465–1471. 2011. View Article : Google Scholar : PubMed/NCBI
19	Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the perugia consensus conference. Antiemetic subcommittee of the multinational association of supportive care in cancer (MASCC). Ann Oncol. 9:811–819. 1998. View Article : Google Scholar : PubMed/NCBI
20	Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, et al: Recommendations for the use of anti-emetics: Evidence-based, clinical practice guidelines. American society of clinical oncology. J Clin Oncol. 17:2971–2994. 1999.PubMed/NCBI
21	Herrstedt J, Aapro MS, Roila F and Kataja VV: ESMO, Guidelines Task Force: ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol. 16(Suppl 1): i77–i79. 2005. View Article : Google Scholar : PubMed/NCBI
22	Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W and Friedman C: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol. 16:754–760. 1998.PubMed/NCBI
23	Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH and Schmoll HJ: A meta-analysis comparing the efficacy of four 5-HT₃-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 15:1023–1033. 2007. View Article : Google Scholar : PubMed/NCBI
24	Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol. 21(Suppl 5): v232–v243. 2010. View Article : Google Scholar : PubMed/NCBI
25	Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, et al: Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 29:4189–4198. 2011. View Article : Google Scholar : PubMed/NCBI
26	Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL and Kuebler JP: Prevention of delayed nausea: A University of Rochester cancer center community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol. 30:3389–3395. 2012. View Article : Google Scholar : PubMed/NCBI
27	Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian group for anti-emetic research. J Clin Oncol. 16:2937–2942. 1998.PubMed/NCBI
28	Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W and Friedman C: Single-dose oral granisetron has equivalent anti-emetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 16:1568–1573. 1998.PubMed/NCBI
29	Vardy J, Chiew KS, Galica J, Pond GR and Tannock IF: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 94:1011–1015. 2006. View Article : Google Scholar : PubMed/NCBI
30	Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, et al: The oral neurokinin-l antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol. 21:4112–4119. 2003. View Article : Google Scholar : PubMed/NCBI